Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo

Raltegravir, an inhibitor of human immunodeficiency virus-1 (HIV-1) integrase, has been used to treat HIV/acquired immunodeficiency syndrome; however, its therapeutic effects on pulmonary fibrosis have not been investigated. In this study, the in vitro effects of raltegravir (RAV) on transforming gr...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Xue Zhang, Haidi Huang, Guanghua Zhang, Defang Li, Hongbo Wang, Wanglin Jiang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-08-01
Subjects:	Raltegravir pulmonary fibrosis NLRP3 inflammation NLRP3 inhibitor HMGB1/TLR4/NF-κB
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2019.00903/full